For Immediate Release

SANTARUS REPORTS THIRD QUARTER 2013 FINANCIAL RESULTS

Total revenues of $98.8 million grew 81% over prior year period

Non-GAAP adjusted earnings of $35.6 million were up 189% over prior year period

Santarus cancels conference call previously scheduled for 5:00 p.m. Eastern Time today

SAN DIEGO (November 7, 2013) – Santarus, Inc. (NASDAQ: SNTS), today reported financial and operating results for the quarter and nine months ended September 30, 2013. Key financial results include:

Santarus Conference Call Cancelled

The previously scheduled Santarus investor conference call at 5:00 p.m. Eastern time (2:00 p.m. Pacific time) today, November 7, 2013 has been cancelled as a result of the joint press release issued today after market close by Santarus and Salix Pharmaceuticals, Ltd. announcing that their Boards of Directors have unanimously approved a definitive merger agreement under which Salix will acquire Santarus through a tender offer followed by a merger for $32.00 in cash for a purchase price of approximately $2.6 billion.

Salix will host a conference call at 4:30 p.m. Eastern Time today, Thursday, November 7, 2013. Interested parties can access the conference call by way of webcast or telephone. The live webcast will be available at www.salix.com. A replay of the webcast will be available at the same location. The telephone numbers to access the live conference call are (800) 319-9003 (U.S. and Canada) or (719) 325-2134 (international). The telephone numbers to access the replay of the call are (888) 203-1112 (U.S. and Canada) or (719) 457-0820 (international). The access code for the call is 612126.

Third Quarter 2013 Financial Results

Total revenues increased to $98.8 million for the third quarter of 2013, compared with $54.7 million for the third quarter of 2012 as indicated below ($ in millions):

Net income for the third quarter of 2013 was $30.3 million and diluted EPS was $0.38. Non-GAAP adjusted earnings for the third quarter of 2013 were $35.6 million and diluted non-GAAP adjusted EPS were $0.45. In the third quarter of 2012 the company reported net income of $9.0 million, diluted EPS of $0.13 and non-GAAP adjusted earnings of $12.3 million, and had diluted non-GAAP adjusted EPS of $0.18.

License fees and royalties of $20.9 million for the third quarter of 2013 included royalties on net sales of GLUMETZA, UCERIS, ZEGERID and FENOGLIDE, the gross margin split on CYCLOSET net sales, and amortization expense. License fees and royalties of $14.8 million for the third quarter of 2012 included royalties on GLUMETZA, ZEGERID and FENOGLIDE net sales, the gross margin split on CYCLOSET net sales, and amortization expense.

Research and development expenses totaled $6.8 million for the third quarter of 2013, compared with $6.2 million for the third quarter of 2012.

Selling, general and administrative (SG&A) expenses were $35.5 million for the third quarter of 2013 and $21.1 million for the third quarter of 2012. The $14.4 million increase in SG&A expenses primarily resulted from the addition of 85 sales representatives in the first quarter of 2013, costs associated with the commercial launch of UCERIS and an increase in legal expenses and recorded stock-based compensation resulting from an increase in the price of the company’s common stock.

Nine Months Ended September 30, 2013

For the nine months ended September 30, 2013, total revenues of $267.6 million increased 81% compared with $147.7 million for the nine months ended September 30, 2012 as indicated below ($ in millions):

Santarus reported net income of $122.6 million, or $1.57 diluted EPS for the first nine months of 2013, which included a one-time income tax benefit of $54.9 million, or $0.70 diluted EPS, recorded as a discrete item in the second quarter of 2013 resulting from the release of the company’s valuation allowance for deferred tax assets. The company reported non-GAAP adjusted earnings of $83.8 million and diluted non-GAAP adjusted EPS of $1.08 for the first nine months of 2013. For the first nine months of 2012 the company reported net income of $13.1 million, or $0.19 diluted EPS, and non-GAAP adjusted earnings of $27.3 million, and had diluted non-GAAP adjusted EPS of $0.40.

As of September 30, 2013, Santarus had cash, cash equivalents and short-term investments of $168.7 million, an increase of approximately $74.0 million in the nine months ended September 30, 2013. The September 30, 2013 cash balance also reflected the repayment in full of $10.0 million in long-term debt associated with the company’s revolving line of credit. Cash, cash equivalents and short-term investments were $94.7 million as of December 31, 2012.

Non-GAAP Financial Measures

In this press release, Santarus used adjusted earnings and diluted adjusted EPS as key operating metrics. Adjusted earnings and diluted adjusted EPS are non-GAAP financial measures. The company believes that the presentation of these non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. The company uses these non-GAAP financial measures in connection with its own budgeting and planning. These non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in conformity with GAAP.

Set forth below is a table reconciling the company’s non-GAAP adjusted earnings to GAAP net income for the three months and nine months ended September 30, 2013 and 2012.

Santarus, Inc.

Reconciliation of GAAP Net Income to Non-GAAP Adjusted Earnings

($ in millions)

(unaudited)

About Santarus

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company’s current commercial efforts are focused on five products. UCERIS^® (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID^® (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists. GLUMETZA^® (metformin hydrochloride extended release tablets) and CYCLOSET^® (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes, and FENOGLIDE^® (fenofibrate) tablets, which is indicated as an adjunct to diet to reduce high cholesterol, are promoted to endocrinologists and other physicians who treat patients with type 2 diabetes. Full prescribing and safety information for Santarus’ products is available at www.santarus.com or by contacting Santarus at 1-888-778-0887.

Santarus’ product development pipeline includes the investigational drug RUCONEST^® (recombinant human C1 esterase inhibitor). A Biologics License Application for RUCONEST for the treatment of acute angioedema attacks in patients with hereditary angioedema is under review by the U.S. Food and Drug Administration with a response expected in April 2014. Santarus is also developing rifamycin SV MMX^®, which is in Phase III clinical testing for treatment of travelers’ diarrhea. In addition, the company has completed a Phase I clinical program with SAN-300, an investigational monoclonal antibody. More information about Santarus is available at www.santarus.com.

Statements included in this press release that are not a description of historical facts are forward-looking statements. These forward-looking statements include statements regarding the planned acquisition of Santarus by Salix Pharmaceuticals, Ltd.

The inclusion of forward-looking statements should not be regarded as a representation by Santarus that its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Santarus’ business, including, without limitation: Santarus’ ability to generate revenues from its currently promoted commercial products and its authorized generic ZEGERID products; risks related to the RUCONEST BLA, including whether the FDA ultimately approves the BLA in a timely matter or at all; Santarus’ ability to timely and successfully complete ongoing and planned clinical studies and otherwise advance the development of its product pipeline; Santarus’ ability to maintain patent protection for its products, including the difficulty in predicting the timing and outcome of ongoing and any future patent litigation; Santarus’ dependence on strategic partners for certain aspects of its development programs, including risks related to their financial stability; adverse side effects, inadequate therapeutic efficacy or other issues related to Santarus’ products that could result in product recalls, market withdrawals or product liability claims; competition from other pharmaceutical or biotechnology companies and evolving market dynamics; other difficulties or delays relating to the development, testing, manufacturing and marketing of, and obtaining and maintaining regulatory approvals for, Santarus’ products; fluctuations in quarterly and annual results; Santarus’ ability to obtain additional financing as needed to support its operations or future product acquisitions; risks and uncertainties as to the timing and completion of the proposed acquisition of Santarus by Salix, including the possibility that competing offers will be made and the possibility that various closing conditions for the transaction may not be satisfied or waived, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended; the effects of disruption caused by the transaction making it more difficult for Santarus to maintain relationships with employees, collaborators, vendors and other business partners; the risk that stockholder litigation in connection with the transaction may result in significant costs of defense, indemnification and liability; and other risks detailed in Santarus’ prior press releases and public periodic filings with the Securities and Exchange Commission.

Santarus^®, FENOGLIDE^®, UCERIS^® and ZEGERID^® are registered trademarks of Santarus, Inc. GLUMETZA^® is a trademark of Biovail Laboratories International S.r.l. licensed exclusively in the United States to Depomed, Inc. CYCLOSET^® is a trademark of VeroScience LLC. MMX^® is a trademark of Cosmo Technologies Limited. RUCONEST^® is a trademark of Pharming Group N.V.

[Tables to follow]

Santarus, Inc.

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

Santarus, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)

(unaudited)

# # #